Results 211 to 220 of about 29,353 (245)

M1-M3 muscarinic acetylcholine receptor-deficient mice: novel phenotypes.

Journal of molecular neuroscience : MN, 2007
The five muscarinic acetylcholine receptors (M1-M5 mAChRs) mediate a very large number of important physiological functions (Caulfield, 1993; Caulfield and Birdsall, 1998; Wess, 2004). Because of the lack of small molecule ligands endowed with a high degree of receptor subtype selectivity and the fact that most tissues or cell types express two or more
Dinesh, Gautam, Alokesh, Duttaroy, Yinghong, Cui, Sung-Jun, Han, Chuxia, Deng, Thomas, Seeger, Christian, Alzheimer, Jürgen, Wess   +7 more
openaire   +1 more source

Cu–Zn superoxide dismutase activates muscarinic acetylcholine M1 receptor pathway in neuroblastoma cells

Molecular and Cellular Neuroscience, 2013
Muscarinic receptors (mAChRs) control several neuronal functions and are widely expressed in the central nervous system (CNS): M1 subtype represents the predominant mAChR in the CNS. Previously, we showed that antioxidant enzyme Cu-Zn superoxide dismutase (SOD1) is secreted by many cellular lines and specifically interacts with cell surface membrane of
DAMIANO, Simona, PETROZZIELLO, TIZIANA, UCCI, VALENTINA, AMENTE, STEFANO, SANTILLO, MARIAROSARIA, MONDOLA, PAOLO   +5 more
openaire   +3 more sources

Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis

Proceedings of the National Academy of Sciences of the United States of America
Significance Multiple sclerosis is a chronic and debilitating neurological disease that results in inflammatory demyelination and neuronal loss. Mechanisms that promote remyelination are being considered as promising therapeutic approaches.
Michael M Poon, Kymmy Lorrain, K. Stebbins, Geraldine C Edu, A. Broadhead, Ariana J Lorenzana, Jeffrey R. Roppe, Jill M Baccei, C. Baccei, Austin Chen, Ari J. Green, D. Lorrain, Jonah R. Chan   +12 more
semanticscholar   +1 more source

Irsogladine activates gap-junctional intercellular communication through M1 muscarinic acetylcholine receptor.

The Journal of Pharmacology and Experimental Therapeutics, 1995
Irsogladine, an agent that protects gastric mucosa against various ulcerogenic stimuli through increasing cyclic AMP in surface mucous cells, has been reported to dose-dependently (10(-7) to 10(-5) M) facilitate gap-junctional intercellular communication (GJIC) in gastric epithelial cells.
F, Ueda, K, Ban, T, Ishima
openaire   +2 more sources

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023

exaly  

71 Purification of recombinant M1 muscarinic acetylcholine receptor

Biochemical Society Transactions, 1998
Edward C. Hulme, Carol A. M. Curtis
openaire   +1 more source

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-Vornhagen, Boris Böll, Victoria Metaxa   +2 more
exaly  

Breast Cancer Statistics, 2022

Ca-A Cancer Journal for Clinicians, 2022
Hyuna Sung, Kimberly D Miller, Rebecca L Siegel   +2 more
exaly  

Current treatment and recent progress in gastric cancer

Ca-A Cancer Journal for Clinicians, 2021
Smita S Joshi, Brian D Badgwell
exaly